Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients

Maryam Motamedi,1 Morteza Hashemzadeh Chaleshtori,1 Sorayya Ghasemi,1 Fariborz Mokarian2 1Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Department of Hematology and Oncology, Faculty of Medicine, Isfahan Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Motamedi M, Hashemzadeh Chaleshtori M, Ghasemi S, Mokarian F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	miRNA-21 miRNA-451 breast cancer biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6cf5d731b19f4920bfcbffd5df5f7920
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6cf5d731b19f4920bfcbffd5df5f7920
record_format	dspace
spelling	oai:doaj.org-article:6cf5d731b19f4920bfcbffd5df5f79202021-12-02T04:44:52ZPlasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients1179-1314https://doaj.org/article/6cf5d731b19f4920bfcbffd5df5f79202019-10-01T00:00:00Zhttps://www.dovepress.com/plasma-level-of-mir-21-and-mir-451-in-primary-and-recurrent-breast-can-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Maryam Motamedi,1 Morteza Hashemzadeh Chaleshtori,1 Sorayya Ghasemi,1 Fariborz Mokarian2 1Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Department of Hematology and Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IranCorrespondence: Sorayya GhasemiCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranTel/fax +98 38 33331471Email sorayya.ghasemi@gmail.comPurpose: MiR-21 and miR-451 are closely associated with tumor initiation, drug resistance, and recurrence of breast cancer (BC). This study was conducted to evaluate the possible value of the plasma level of miR-21 and miR-451 as potential biomarkers for the detection of primary and recurrent BC.Patients and methods: In this descriptive–analytical study, the plasma level of miR-21 and miR-451 was measured in 23 primary BC patients, 24 recurrent (local/distant metastasis) BC patients, and 24 aged-match women as healthy controls using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Finally, data were analyzed using SPSS software, and the area under the receiver operating characteristic (ROC) curve of miRNAs was measured.Results: The plasma level of miR-21 was significantly increased in both groups of primary (P<0.001) and recurrent (P<0.001) BC patients in comparison with healthy women. However, the plasma level of miR-451 was not significantly changed in primary (P=0.065) and recurrent (P=0.06) BC patients than healthy controls. The elevation of both miR-21 and miR-451 plasma level was not significantly changed in recurrent patients compared with non-recurrent (primary) patients (P=0.481, and P=1, respectively). Based on the ROC analyses, the areas under the curves (AUC) for miR-21 in discriminating primary BC and recurrent BC patients from healthy controls were 0.828 (95% CI: 0.712 to 0.944) and 0.865 (95% CI: 0.756 to 0.974), respectively.Conclusion: These data indicating that plasma miR-21 may be useful as a biomarker for the detection of both primary and recurrent BC. However, plasma miR-451 lacks enough sensitivity in the detection of primary and recurrent BC, and more studies are needed in this area.Keywords: miRNA-21, miRNA-451, breast cancer, biomarkerMotamedi MHashemzadeh Chaleshtori MGhasemi SMokarian FDove Medical PressarticlemiRNA-21miRNA-451breast cancerbiomarkerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 293-301 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	miRNA-21 miRNA-451 breast cancer biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	miRNA-21 miRNA-451 breast cancer biomarker Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Motamedi M Hashemzadeh Chaleshtori M Ghasemi S Mokarian F Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
description	Maryam Motamedi,1 Morteza Hashemzadeh Chaleshtori,1 Sorayya Ghasemi,1 Fariborz Mokarian2 1Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran; 2Department of Hematology and Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, IranCorrespondence: Sorayya GhasemiCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranTel/fax +98 38 33331471Email sorayya.ghasemi@gmail.comPurpose: MiR-21 and miR-451 are closely associated with tumor initiation, drug resistance, and recurrence of breast cancer (BC). This study was conducted to evaluate the possible value of the plasma level of miR-21 and miR-451 as potential biomarkers for the detection of primary and recurrent BC.Patients and methods: In this descriptive–analytical study, the plasma level of miR-21 and miR-451 was measured in 23 primary BC patients, 24 recurrent (local/distant metastasis) BC patients, and 24 aged-match women as healthy controls using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Finally, data were analyzed using SPSS software, and the area under the receiver operating characteristic (ROC) curve of miRNAs was measured.Results: The plasma level of miR-21 was significantly increased in both groups of primary (P<0.001) and recurrent (P<0.001) BC patients in comparison with healthy women. However, the plasma level of miR-451 was not significantly changed in primary (P=0.065) and recurrent (P=0.06) BC patients than healthy controls. The elevation of both miR-21 and miR-451 plasma level was not significantly changed in recurrent patients compared with non-recurrent (primary) patients (P=0.481, and P=1, respectively). Based on the ROC analyses, the areas under the curves (AUC) for miR-21 in discriminating primary BC and recurrent BC patients from healthy controls were 0.828 (95% CI: 0.712 to 0.944) and 0.865 (95% CI: 0.756 to 0.974), respectively.Conclusion: These data indicating that plasma miR-21 may be useful as a biomarker for the detection of both primary and recurrent BC. However, plasma miR-451 lacks enough sensitivity in the detection of primary and recurrent BC, and more studies are needed in this area.Keywords: miRNA-21, miRNA-451, breast cancer, biomarker
format	article
author	Motamedi M Hashemzadeh Chaleshtori M Ghasemi S Mokarian F
author_facet	Motamedi M Hashemzadeh Chaleshtori M Ghasemi S Mokarian F
author_sort	Motamedi M
title	Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
title_short	Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
title_full	Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
title_fullStr	Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
title_full_unstemmed	Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients
title_sort	plasma level of mir-21 and mir-451 in primary and recurrent breast cancer patients
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/6cf5d731b19f4920bfcbffd5df5f7920
work_keys_str_mv	AT motamedim plasmalevelofmir21andmir451inprimaryandrecurrentbreastcancerpatients AT hashemzadehchaleshtorim plasmalevelofmir21andmir451inprimaryandrecurrentbreastcancerpatients AT ghasemis plasmalevelofmir21andmir451inprimaryandrecurrentbreastcancerpatients AT mokarianf plasmalevelofmir21andmir451inprimaryandrecurrentbreastcancerpatients
_version_	1718401086014881792

Plasma Level Of miR-21 And miR-451 In Primary And Recurrent Breast Cancer Patients

Ejemplares similares